Bayer announces positive topline results for nubeqa® (darolutamide) from phase iii trial in men with metastatic hormone-sensitive prostate cancer (mhspc)

Whippany, n.j.--(business wire)--the phase iii aranote trial, investigating nubeqa® (darolutamide) plus androgen deprivation therapy (adt) in patients with metastatic hormone-sensitive prostate cancer (mhspc), has met its primary endpoint of radiological progression-free survival (rpfs). nubeqa plus adt demonstrated a statistically significant and clinically meaningful increase in rpfs compared to placebo plus adt. results were consistent with nubeqa's established safety profile with no new sign.
ADT Ratings Summary
ADT Quant Ranking